IDIOPATHIC HYPERSOMNIA · White paper
Idiopathic Hypersomnia Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About idiopathic hypersomnia — and why its trials are hard
Idiopathic hypersomnia (IH) is a chronic neurological sleep disorder defined by persistent excessive daytime sleepiness (EDS) not explained by nighttime sleep quantity or quality. Hallmarks include prolonged, non-refreshing sleep, severe sleep inertia (sleep drunkenness), poor response to naps and conventional stimulants, and, unlike narcolepsy type 1, an absence of cataplexy and REM-related phenomena. Diagnosis relies on the Multiple Sleep Latency Test and prolonged sleep documentation after excluding other causes. IH is under-recognized and long lacked any FDA-approved therapy, so most patients were managed off-label with wake-promoting agents such as modafinil, armodafinil, and methylphenidate. That changed in 2021 when low-sodium oxybate (Xywav) became the first and, to date, only FDA-approved treatment specifically for IH. Trials face notable design challenges: heterogeneous phenotypes, reliance on subjective scales like the Epworth Sleepiness Scale and the IH Severity Scale, and difficulty objectively capturing sleep inertia. Randomized-withdrawal designs, validated composite scales, and better core-symptom endpoints are increasingly used to secure regulatory success.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Low-sodium oxybate (calcium, magnesium, potassium, sodium oxybates) (Xywav) | 2021 | First and only FDA-approved therapy specifically for IH in adults | Phase 3 randomized-withdrawal study (NCT03533114) | Change in Epworth Sleepiness Scale (ESS) during double-blind withdrawal | Mean ESS change -6.5 (95% CI -8.0 to -5.0; P<0.0001); IH Severity Scale improved ~12 points (P<0.0001) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in idiopathic hypersomnia development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Pitolisant (histamine H3-receptor antagonist) — INTUNE Phase 3 (NCT05156047) | Failed to meet the primary endpoint of significant EDS reduction versus placebo; not approved for IH | Benefit seen only on some secondary outcomes; insufficient effect on core EDS endpoint |
| Once-nightly sodium oxybate (LUMRYZ, extended-release) — REVITALYZ Phase 3 (ongoing) | Investigational for IH (orphan drug designation only); not yet FDA-approved for this indication | Efficacy/safety in IH still under evaluation; approved to date only for narcolepsy (unverified for IH) |
| Serdexmethylphenidate/dexmethylphenidate (KP1077) — Phase 2 (NCT05849808) | Investigational stimulant prodrug for IH; not FDA-approved | Development ongoing; efficacy on IH core symptoms not yet established (unverified) |
Choosing the right endpoint
Primary endpoints that matter in idiopathic hypersomnia trials
- Epworth Sleepiness Scale (ESS) — Self-reported 0-24 scale of daytime sleep propensity; the primary endpoint in the Xywav trial
- Idiopathic Hypersomnia Severity Scale (IHSS) — IH-specific instrument capturing sleepiness, sleep inertia, and long sleep
- Patient Global Impression of Change (PGIc) — Global patient-rated measure of overall improvement
- Sleep inertia measures — Assess sleep drunkenness, a core and hard-to-quantify IH symptom
- Functional Outcomes of Sleep Questionnaire (FOSQ) — Captures the impact of sleepiness on daily functioning and quality of life
How iNGENū runs idiopathic hypersomnia trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Idiopathic Hypersomnia clinical trials — FAQs
Is there an FDA-approved treatment for idiopathic hypersomnia?
What are the main endpoints in IH trials?
Why is IH difficult to study in clinical trials?
Ready to discuss your idiopathic hypersomnia trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal